Previous 10 | Next 10 |
- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p<0.0001) and clinically me...
2023-08-02 10:45:00 ET Summary The US stock market (using the Russell 3,000 as a proxy) has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. the peak market cap for the US stock market was $51.5 trillion...
- BridgeBio met with the U.S. Food and Drug Administration (FDA) to discuss the use of glycosylated αDG levels as a surrogate endpoint; based on this meeting, the Company believes there is potential to pursue Accelerated Approval in the U.S. for BBP-418 - BridgeBio has dosed the fi...
2023-07-26 09:11:45 ET Summary Tech stock momentum have experienced significant downturns over the past week, with Nasdaq-100 constituents glowing red. There are ample suggestions of sector rotation in play, which a variety of analytical filters also bear out. Spreads between ...
2023-07-21 10:44:42 ET Shares of BridgeBio Pharma (NASDAQ: BBIO) were up 90% for the week as of 10:25 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence . The biotech company, which focuses on therapies for oncology and genetic diseases, repo...
2023-07-17 18:42:44 ET Summary Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy; NDA filing expected before end of 2023. Results from the phase 3 ATTRibute-CM ...
2023-07-17 14:56:32 ET Summary BridgeBio Pharma, Inc. has reported encouraging results from its Phase 3 ATTRibute-CM study of acoramidis, a potential treatment for Transthyretin amyloid cardiomyopathy. The company's financial health is robust, with cash and equivalents increasing ...
2023-07-17 12:05:29 ET Shares of BridgeBio ( NASDAQ: BBIO ) shot up 80% in midday trading Monday after the biotech company said it plans to file for US regulatory approval of its drug acoramidis by the end of the year after releasing positive Phase 3 data for the drug in the treatme...
2023-07-17 10:07:51 ET Gainers: ProMIS Neurosciences ( PMN ) +149% . BridgeBio Pharma ( BBIO ) +62% . Acumen Pharmaceuticals ( ABOS ) +60% . Healthcare Triangle ( HCTI ) +42% . argenx ( ARGX ) +30% . Losers: Apellis P...
2023-07-17 09:09:09 ET The stock market has been on a solid upward trajectory recently, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) has largely been leading the way. With so many stocks in high-growth areas like technology, the Nasdaq has been at the center of key trends driving s...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...